||
01. | 2022 | 10 篇 | 5.051% |
02. | 2021 | 45 篇 | 22.727% |
03. | 2020 | 42 篇 | 21.212% |
04. | 2019 | 36 篇 | 18.182% |
05. | 2018 | 26 篇 | 13.131% |
06. | 2017 | 16 篇 | 8.081% |
07. | 2016 | 12 篇 | 6.061% |
08. | 2015 | 8 篇 | 4.040% |
09. | 2014 | 1 篇 | 0.505% |
10. | 2008 | 1 篇 | 0.505% |
11. | 2007 | 1 篇 | 0.505% |
01. | int j mol sci | 13 篇 | 6.566% |
02. | front immunol | 10 篇 | 5.051% |
03. | clin cancer res | 6 篇 | 3.030% |
04. | nature | 6 篇 | 3.030% |
05. | cancer immunol res | 5 篇 | 2.525% |
06. | j immunother cancer | 5 篇 | 2.525% |
07. | nat commun | 5 篇 | 2.525% |
08. | mol ther | 4 篇 | 2.020% |
09. | theranostics | 4 篇 | 2.020% |
10. | br j cancer | 3 篇 | 1.515% |
01. | 美国 | 81 篇 | 40.909% |
02. | 中国 | 37 篇 | 18.687% |
03. | 英国 | 21 篇 | 10.606% |
04. | 德国 | 16 篇 | 8.081% |
05. | 日本 | 16 篇 | 8.081% |
06. | 荷兰 | 11 篇 | 5.556% |
07. | 意大利 | 11 篇 | 5.556% |
08. | 法国 | 9 篇 | 4.545% |
09. | 比利时 | 7 篇 | 3.535% |
10. | 瑞典 | 6 篇 | 3.030% |
01. | 中国上海 | 7 篇 | 3.535% |
02. | 中国武汉 | 5 篇 | 2.525% |
03. | 中国北京 | 4 篇 | 2.020% |
04. | 中国南京 | 4 篇 | 2.020% |
05. | 中国广州 | 3 篇 | 1.515% |
06. | 中国深圳 | 3 篇 | 1.515% |
07. | 中国成都 | 3 篇 | 1.515% |
08. | 中国太原 | 2 篇 | 1.010% |
09. | 中国长春 | 2 篇 | 1.010% |
10. | 中国苏州 | 2 篇 | 1.010% |
01. | Neoplasms | 198 篇 | 100.000% |
02. | Humans | 188 篇 | 94.949% |
03. | Animals | 117 篇 | 59.091% |
04. | Immunotherapy | 89 篇 | 44.950% |
05. | Molecular Targeted Therapy | 58 篇 | 29.293% |
06. | Mice | 44 篇 | 22.222% |
07. | Tumor Microenvironment | 44 篇 | 22.222% |
08. | Programmed Cell Death 1 Receptor | 37 篇 | 18.687% |
09. | Immune Checkpoint Inhibitors | 36 篇 | 18.182% |
10. | Signal Transduction | 35 篇 | 17.677% |
Archiver|手机版|科学网 ( 京ICP备07017567号-12 )
GMT+8, 2024-4-23 19:49
Powered by ScienceNet.cn
Copyright © 2007- 中国科学报社